KeenMind - Inattention Trial

1 KeenMind shows a calming effect1 KeenMind demonstrated a signifi cant reduction in state anxiety compared to placebo, suggesting that it can be benefi cial in times of stress or mild In a 2014 study, the 640mg dose (equivalent to 4 capsules of KeenMind ) showed reduction in cortisol levels suggesting a physiological mechanism for stress reduction with uses for KeenMind Students to facilitate learning. Assists concentration, focus and keeping to task. May be useful during times of stress. Multitasking Adults Women returning to paid work, professionals starting new jobs - Supports memory, concentration and mental clarity. Useful during times of stress and mild anxiety. Elderly to assist in delay of cognitive defined safety profile Studies indicate that cognitive e ects are achieved with reports of no reports of clinically relevant side e ects Suitable for use in children and adults, including the elderlyDosage Adults: 2 capsules with breakfast Children over 7 years: 1 capsule daily with breakfast.

2 E ects of KeenMind may be felt within hours, however daily use is recommended. Full benefi ts expected after 1 to 3 GROWN FROM SCIENCE KeenMind is clinically proven to support memory, concentration and learning retention1,2 KeenMind contains a specific extract of Bacopa monnieri ( CDRI 08) that is the result of 40 years of research.* More recently KeenMind has been studied in double-blind placebo-controlled clinical studies at the Brain Sciences Institute at Swinburne is clinically proven to support cognitive performance1 KeenMind demonstrates improvement in working memory2 KeenMind (CDRI 08)Supports Memory, Concentration and Learning Retention Summary Clinically proven to support memory, concentration and learning retention1,2 Clinical results show KeenMind supports cognitive performance1 Significantly improves working memory2 Shown to be useful during times of stress and mild anxiety1,3* The extract CDRI 08 was researched in 1974 and is still the subject of ongoing clinical improvement in cognitive variables after 12 weeks of treatment with KeenMindSignificant ImprovementSpeed of visual information processingLearning rateMemory consolidationForgetting ratep < Working Memory factor.

3 Change from baseline score post-treatmentKeenMind improvement in Working Memory after 12 weeks0123456 PlaceboKeenMindPlaceboKeenMind0246810121 4 BaselineT = 12 weeksFL0000015 6/2015PO Box 1027 Crows Nest NSW 1585, Australia 1800 334 224 fl ReviewAndrea ZangaraBSc (Clinical Psychology) Research Scholar, Medicinal Plant Research Centre, Newcastle University, UKResearch Fellow, Brain Sciences Institute, Swinburne University, AUSpecific FormulationKeenMind contains a specifi c extract of Bacopa monnieri (Bacopa) that is the result of over 40 years of clinical research and has been examined in 6 clinical trials. This extract, referred to as CDRI 08 in the scientifi c literature is manufactured in Switzerland following professional quality standards. This helps to ensure that each batch of KeenMind is of a consistent high of Action6-10 Although the exact mechanism of action of Bacopa on cognitive processes has not yet been determined, evidence suggests that they are multiple and complex.

4 Clinical StudiesOver the last 40 years the CDRI has researched and developed the modern use of Bacopa. The scientifi c evidence for the memory enhancing e ects of Bacopa is based on pre-clinical studies, and is confi rmed by numerous clinical trials conducted in include: Enhanced memory, reduced anxiety and mental fatigue and increased work output. Enhanced memory and improved learning ability for children11 The fi rst double blind placebo-controlled Trial for KeenMind was published in This study was conducted in Australia by Professor Con Stough and colleagues at Swinburne University to investigate the memory enhancing e ects in 46 healthy subjects aged between 18 and 60 years. Results showed signifi cantly improved speed of visual information processing, learning rate and memory consolidation, and decreased anxiety; maximal e ects were evident after 12 weeks. Roodenrys and colleagues replicated the memory enhancing e ects of KeenMind in 76 participants aged between 40 and 65 They reported a signifi cant decrease in the rate of forgetting newly acquired information after 90 days of treatment in a sample of older individuals than previously used by Stough and colleagues (2001).

5 A study on 62 healthy participants was conducted at the Brain Sciences Institute at Swinburne University in Melbourne Australia. Cognitive Drug Research (CDR), which is a computerised battery of cognitive tests, of proven validity, were used to assess the e ects of KeenMind compared to a placebo, in a randomised double-blind, placebo-controlled Trial (the gold standard in clinical research). After 90 days of treatment with 2 capsules of KeenMind the participants had signifi cantly improved performance on working memory (the ability to hold information online in the brain and actually do something with that information) and visual information processing (a measure of the ability to sustain attention). Slowed information processing is one of the most prominent cognitive defi cits in the memory is our mental workspace to process, store and recall information. That is why it also plays a key role in learning.

6 In a 2014 acute Trial , KeenMind improved cognitively demanding tasks 1h and 2h post consumption, indicating an early cognitive enhancing e ect. The performance-driven tasks were presented through the MTF platform, which is a computerized test of four di erent cognitive tasks to be completed in a total time period of 20 KeenMind also improved performance at 1 hour post-treatment, suggesting faster information processing and higher also produced a signifi cant reduction in state anxiety compared to placebo, suggesting that it can be benefi cial in times of stress or mild is the result of 4 decades of research worldwide and now 6 clinical studies have confi rmed the potential of this complementary medicine. These rigorously designed trials have proven that KeenMind helps improve memory and other measures of brain function. KeenMind (CDRI 08)Clinically proven to support memory, concentration and learning retentionREFERENCES 1.

7 Stough et al. Psychopharmacology (Berl.). 2001, 156(4):481-484 2. Stough et Res. 2008 122(12):1629-1634 3. :)4(82 ;4102 hcraeseR yparehtotyhP .la te S nosneB 4. Rai D et Biochem Behav. 2003 Jul;75(4):823-30 5. Dulcy et al. Journal of Neuroscience Research 2012 90:2053 2064 6. Jyoti A et al. Neuro Toxicology 2006, 27: 451-457 7. Will iams R et al. The Royal Society of Chemistry: Food & Function. 2014. Published online DOI: 8. Rajan et al. Neurochem Res 201136:2136 2144 9. 7712 7612:73;2102 .seR .mehcorueN .la te J ihteerP 10. Saraf, et al. Neurochemical Research 2010. 35, 279 87 11. Sharma et al, J. Indian Med. 1987 1:12. 12. Roodenrys et al 2002. Neuropsychopharmacology 27(2) Mechanisms of ActionAnxiolytic4 Anti-inflammatory7 Adaptogenic4 Modulation of Cholinergic & Serotonergic Systems5,8,9 Antioxidant5,6 Neuroprotective5,6,10 KeenMind Calming Effect1 State Anxiety0123456 PlaceboKeenMindPlaceboKeenMind0246810121 4 BaselineT = 12 weeks